Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC
Open Access
- 8 May 2020
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 74 (1), 19-24
- https://doi.org/10.1136/jclinpath-2020-206607
Abstract
Background Peritoneal metastasis from pancreatic cancer (PM-PC) may be treated with repeated pressurised intraperitoneal aerosol chemotherapy (PIPAC). Utility of next-generation sequencing (NGS) to detect cancer-related mutations in peritoneal quadrant biopsies (QBs) and peritoneal fluid (PF) after systemic and PIPAC treatment has not been evaluated. Around 90% of pancreatic cancers (PCs) harbour a KRAS mutation, making PC ideal for the evaluation of this aspect. Aims Evaluation of PM-PC in terms of (1) histological response to PIPAC using Peritoneal Regression Grading Score (PRGS), (2) clinical characteristics and (3) frequency of mutations in QBs and PF before and after PIPAC. Methods Peritoneal QBs and PF were obtained prior to each PIPAC. NGS for 22 cancer-related genes was performed on primary tumours, QBs and PFs. Response was assessed by the four-tiered PRGS. Results Sixteen patients treated with a median of three PIPAC procedures were included. The mean PRGS was reduced from 1.91 to 1.58 (p=0.02). Fifty-seven specimens (13 primary tumours, 2 metastatic lymph nodes, 16 PFs and 26 QB sets) were analysed with NGS. KRAS mutation was found in 14/16 patients (87.50%) and in QBs, primary tumours and PF in 8/12 (66.67%), 8/13 (61.53%) and 6/9 (66.67%). The median overall survival was 9.9 months (SE 1.5, 95% CI 4.9 to 13.9). Conclusion PIPAC induces histological response in the majority of patients with PM-PC. KRAS mutation can be found in PM-PC after PIPAC at a frequency similar to the primaries. NGS may be used to detect predictive mutations in PM-PC of various origins, also when only post-PIPAC QBs or PFs are available.Keywords
Funding Information
- Odense Pancreas Center
This publication has 26 references indexed in Scilit:
- Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasisColorectal Disease, 2016
- Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patientsNature Communications, 2015
- Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 studyGynecologic Oncology, 2015
- Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic CancerThe Oncologist, 2015
- Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencingLeukemia & Lymphoma, 2014
- Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for EfficacyAnnals of Surgical Oncology, 2013
- Description of a novel approach for intraperitoneal drug delivery and the related deviceSurgical Endoscopy, 2012
- The Molecular Targets for the Diagnosis and Treatment of Pancreatic CancerGut and Liver, 2010
- Targeting the c-Met Signaling Pathway in CancerClinical Cancer Research, 2006
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003